Test drops to thin lung mucus in severe COVID-19
Part of Infections, Lungs & breathing clinical trials.
This Phase 2 trial tests rhDNase (a medication similar to Pulmozyme) to improve outcomes and reduce the risk of death in people with severe COVID-19 causing breathing failure. It’s meant for adults who need high-flow oxygen or a breathing machine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You need high-flow oxygen (more than 6 liters through a nasal tube) or a breathing machine
- You have COVID-19 based on your clinician’s diagnosis and either a positive PCR test or typical COVID-19 symptoms with matching chest CT findings
- You cannot have a known allergy to Pulmozyme (rhDNase)
- You should not be expected to die within 48 hours, and your doctor must feel it’s appropriate to enroll
- You should not be taking part in another drug trial with an investigational medicine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early (Phase 1) study tests AVM0703 in adults who are very sick with lung failure caused by COVID-19 or influenza (flu). It aims to see if the treatment is safe and potentially helpful when standard rescue breathing treatments are not enough.
This study looks at how hard people with COVID-19 are working to breathe when they have serious breathing trouble but are not yet fully on a breathing machine. The results may help doctors better understand breathing support needs and improve care.
This trial tests whether a heart-lung machine called venovenous ECMO can help people with severe breathing failure get less sedated, get extubated (have the breathing tube removed), and start moving. It’s for certain adults who are on a ventilator for a short time and have specific oxygenation problems.
This study tests if non-invasive breathing support (like a mask or high-flow oxygen) can help hospitalized patients with low oxygen levels due to COVID-19, without needing a breathing tube. It aims to see how well it works and what risks it may have.
This trial tests whether immune-supporting treatment made from exosomes can help people with critically severe COVID-19 and lung damage. If you qualify, you may receive this therapy as part of the study to see if it improves outcomes.
This trial tests whether inhaled dornase alfa can reduce the risk of respiratory (lung) failure in adults with severe trauma who are on a breathing machine in the ICU. If it works, it may help patients spend less time with dangerous breathing complications.
Hear when a new Covid19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.